DATA GRAPHICS | Data Byte
Cardiovascular target Lp(a) attracts another pharma in Lilly
With Lilly/Verve deal, three pharmas are now in the small but growing Lp(a) pipeline
June 16, 2023 12:16 AM UTC
Eli Lilly has become at least the third major biopharma company to throw its weight behind cardiovascular disease target Lp(a), signing a deal with Verve to develop an in vivo gene editing program against the target.
Though the pipeline of therapeutic candidates against Lp(a) remains small, with five programs disclosed so far, the companies behind those products are not, with Eli Lilly and Co. (NYSE:LLY) joining Amgen Inc. (NASDAQ:AMGN) and Novartis AG (SIX:NOVN; NYSE:NVS) as the third large biopharma pursuing the target...
BCIQ Company Profiles
BCIQ Target Profiles